不同剂量来曲唑用于多囊卵巢综合征促排卵对内分泌的影响被引量：5

下载PDF

导出

摘要目的比较3种不同剂量来曲唑用于多囊卵巢综合征(PCOS)患者促排卵时对内分泌激素水平的影响及促排卵效果。方法选取2014年6月至2015年6月在该院生殖内分泌门诊就诊拟行促排卵的84例PCOS患者为研究对象,按用药剂量不同分为三组。A组(23例)与B组(34例)患者在月经第3天分别给予来曲唑2.5、5.0 mg/d,共5 d,C组(27例)患者在月经第3天顿服来曲唑20 mg。观察比较三组患者月经第3天和人绒毛膜促性腺激素(HCG)注射日血清黄体生成素、雌二醇、睾酮水平变化及排卵率和周期妊娠率情况。结果月经第3天用药后,三组患者黄体生成素、雌二醇、睾酮水平比较,差异均无统计学意义(P>0.05);随着服用来曲唑总量的增加,三组患者在HCG注射日睾酮水平均有升高趋势,但差异无统计学意义(P>0.05),雌二醇、黄体生成素水平及排卵率和周期妊娠率比较,差异均无统计学意义(P>0.05)。结论 3种不同剂量来曲唑用于PCOS患者促排卵并不会引起黄体生成素、雌二醇、睾酮水平的不同,促排卵效果相当,不会造成内分泌失调。

作者刘宝孙文洁林奕郝丽娟

机构地区重庆市妇幼保健院生殖内分泌科

出处《现代医药卫生》 2016年第20期3176-3178,共3页 Journal of Modern Medicine & Health

基金重庆市卫生局医学科研基金资助项目(2010-2-323)

关键词三唑类/投药和剂量多囊卵巢综合征排卵诱导睾酮来曲唑

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献14

1Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate[J]. FertilSteril, 2001,75 ( 2 ) : 305 -309.
2Healey S, Tan SL, Biljan MM, et al.Letrozole and gonadotropins :what is the ideal patient protocol?[J]. FertilSteril, 2003,80(6) : 1339.
3Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to oolvcvstic ovary syndrome[J1. FertilSteril. 2004.81 ( 1 ) : 19-25.
4Mittally MF,Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation[J]. FertilSteri1,2005,83 ( 1 ) : 229-231.
5崔琳琳,陈子江.多囊卵巢综合征的临床分型及意义[J].中华妇产科杂志,2010,45(8):623-625. 被引量：30
6Winer EP,Hudis C ,Burstein HJ,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004[J]. J Clin Oncol,2005,23(3) :619-629.
7Lamb HM, Adkins JC. Letrozole. A review of its use in postmenopausal women with advanced breast cancer[J].Drugs, 1998,56 (6) : 1125-1140.
8Vendola KA,Zhou J, Adesanya OO,et al. Androgens stimulate early stages of follicular growth in the primate ovary[J]. J Clin Invest, 1998,101 (12) : 2622-2629.
9Mazerbourg S, Bondy CA, Zhou J, et al. The insulin-like growth factor system: a key determinant role in the growth and selection of ovarian fol- licles? A comparative species study[J]. Reprod Domest Anim,2003,38 (4) : 247-258.
10Stocco C. Ammatase expression in the ovary : hormonal and molecular reg- ulation[J]. Steroids, 2008,73 ( 5 ) : 473 -487.

二级参考文献56

1胡颜霞,张展,贾莉婷.来曲唑诱导多囊卵巢综合征大鼠模型的研究[J].中国妇幼保健,2006,21(7):957-959. 被引量：34
2Salley KE,Wickham EP,Cheang KI,et al.Glucose intolerance in polycystic ovary syndrome:a position statement of the Androgen Excess Society.J Clin Endocrinol Metal,2007,92:4546-4556.
3Dokras A.Cardiovascular disease risk factors in polycystic ovary syndrome.Semin.in Reprod Med,2008,26:39-44.
4Chen MJ,Yang WS,Yang JH,et al.Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.Hypertension,2007,49:1442-1447.
5Stein IF,Leventhal ML.Amenorrhoea associated with bilateral polycystic ovaries.Am J Obstet Gynecol,1935,29:181-191.
6Keettel WC,Bradbury JT,Stoddard FJ.Observations on the polycystic ovary syndrome.Am J Obstet Gynecol,1957,73:954-962.
7Milsom SR,Sowter MC,Carter MA,et al.LH levels in women with polycystic ovarian syndrome:have modern assays made them irrelevant? BJOG,2003,110:760-764.
8Swanson M,Sauerbrei EE,Cooperberg PL.Medical implications of ultrasonically detected polycystic ovaries.J Clin Ultrasound,1981,9:219-222.
9el Tabbakh GH,Lotfy I,Azab I,et al.Correlation of the ultrasonic appearance of the ovaries in polycystic ovarian disease and the clinical,hormonal,and laparoscopic findings.Am J Obstet Gynecol,1986,154:892-895.
10Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.J Clin Endocrinol Metab,1980,50:113-116.